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A B S T R A C T
This study investigated the seroprevalence of
antibodies against Anaplasma phagocytophilum in
Berlin ⁄Brandenburg, north-eastern Germany.
During 1994–2001, 422 sera from patients with
proven tick-exposure (specimens with antibodies
against Borrelia burgdorferi) were compared with
249 control sera. Using indirect fluorescent anti-
body testing, significantly more positive samples
were detected among Borrelia antibody-positive
specimens (4.5%, 95% CI 2.5–6.5%) than among
controls (1.2%, 95% CI 0.5–1.9%; p < 0.05). While
six (2.2%, 95%CI 1.3–3.1%) samples were positive
among Borrelia antibody-positive sera between
1994 and 1997, 13 (8.7%, 95% CI 6.9–10.5%) were
positive between 1998 and 2001 (p < 0.01), indica-
ting an uneven annual seroprevalence.
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Anaplasma phagocytophilum is transmitted by
Ixodes ticks and causes human granulocytic
anaplasmosis (HGA) [1]. Serology can confirm
the diagnosis of HGA, with indirect fluorescent
antibody testing (IFA) being used most frequently
[1]. In Europe, 22 confirmed cases of HGA have
been described [2,3]. While no patients with HGA
have been documented to date in Germany,
HGA-specific antibodies have been detected in
serological studies [4–6]. Additionally, Ixodes
ricinus ticks infected with A. phagocytophilum,
some of which were co-infected with Borrelia
burgdorferi, have been found in Germany [3]. The
present study aimed to determine the seroprev-
alence of HGA during an 8-year period in the
Berlin ⁄Brandenburg area where borreliosis is
endemic [7].
As I. ricinus transmits the agents of both HGA
and borreliosis, Borrelia antibody-positive sera
were used to determine the prevalence of HGA-
specific antibodies in patients with a proven
tick-bite, and this was compared with the sero-
prevalence found in individuals at common risk
for tick-bites. B. burgdorferi-specific antibodies
were determined by ELISA (DakoCytomation,
Hamburg, Germany) and by IFA (DakoCytoma-
tion or Gull Laboratories, Fresenius, Bad Hom-
burg, Germany) at dilutions ‡ 64. Control samples
comprised: (i) 107 sera collected in 1996–2001 that
contained antibodies against a different spiro-
chaete (Treponema pallidum) and that were reac-
tive in the TPHA ⁄TPPA test (MAST Diagnostica,
Reinfeld, Germany) at dilutions ‡ 160, with
confirmation by FTA-Abs (MAST Diagnostica);
and (ii) 142 samples with IgG ELISA titres
(Medac International, Wedel, Germany) against
different obligate intracellular bacteria (Chlamy-
dia ⁄Chlamydophila spp.). Donors of Borrelia-pos-
itive and control sera did not differ significantly
with respect to age or gender. IFA kits (Focus
Diagnostics; Genzyme Virotech, Ru¨sselsheim,
Germany) were used to detect IgG and IgM
antibodies against A. phagocytophilum. Slides were
evaluated independently by two observers using
a Zeiss fluorescence microscope (50 W mercury
bulb; 390–420 nm excitation filter, 450 nm barrier
filter, · 630 magnification). As suggested by the
manufacturer, titres ‡ 64 and ‡ 20 were consid-
ered positive for HGA-specific IgG and IgM,
respectively. Nineteen of 422 samples positive for
Borrelia antibody (4.5%, 95% CI 2.5–6.5%) and
three of 249 control samples (1.2%, 95% CI 0.5–
1.9%) had IgG titres ‡ 64 (p < 0.05; chi-square
test) (Table 1). Similar data have been reported
from other European countries [8–11]. Four sam-
ples (no control specimen) also contained IgM
against A. phagocytophilum. The three HGA-pos-
itive control samples (one T. pallidum-positive,
two Chlamydia ⁄Chlamydophila-positive) were
negative for antibodies against B. burgdorferi.
Although serological cross-reactions have not
been reported between Chlamydia ⁄Chlamydophila
and Anaplasma, these cannot be excluded at
present.
The 22 HGA IgG-positive specimens were
examined using the MarBlot western blot test
(MarDx ⁄Trinity Biotech, Carlsbad, CA, USA).
Seven specimens (31.8%; six Borrelia antibody-
positive and one control) showed bands at
42 ⁄ 44 kDa and were considered to be positive
(Table 1). Similar discrepant IFA and western blot
results have been documented previously [8], and
probably result from differences in the sensitivity
and specificity of the two test systems [12,13].
When the case records of the 22 HGA IgG-
positive patients were studied, five patients were
classified as probable HGA cases according to
CDC definitions [14] (Table 1). Elevated liver
Table 1. Patients with antibodies against Anaplasma phag-
ocytophilum according to the indirect fluorescent antibody
(IFA) test
Patient
Gender ⁄
age
IFA
IgG
IFA
IgM
Western
blot
Data from
patient’s history
1 (B+) f ⁄ 18 256 – – te, f, c (CAFE, CDC)a
2 (B+) f ⁄ 34 64 – + te
3 (B+) f ⁄ 64 128 – –
4 (B+) m ⁄ 40 64 – – te, ecm
5 (B+) f ⁄ 48 64 – – te, ecm, le
6 (B+) f ⁄ 72 512 – + te
7 (B+) f ⁄ 51 64 20 + te, f, le (CDC)a
8 (B+) f ⁄ 43 128 – – te
9 (B+) m ⁄ 70 128 20 + te, f, c (CAFE, CDC)a
10 (B+) f ⁄ 56 128 – – te
11 (B+) f ⁄ 20 64 20 –
12 (B+) m ⁄ 61 64 20 + te, f, le (CDC)a
13 (B+) m ⁄ 53 512 – –
14 (B+) m ⁄ 21 64 – + te
15 (B+) m ⁄ 36 128 – – te
16 (B+) f ⁄ 74 64 – –
17 (B+) m ⁄ 31 128 – – te, f, le (CAFE, CDC)a
18 (B+) f ⁄ 22 64 – –
19 (B+) f ⁄ 84 128 – – te, c
20 (B–) f ⁄ 19 64 – +
21 (B–) m ⁄ 24 256 – –
22 (B–) m ⁄ 77 64 – –
(B+), positive serological results for borreliosis; (B–), negative serological results for
borreliosis.
aProbable HGA cases on the basis of either the CAFE Society criteria [15] (IFA ‡ 80;
te, history of tick-exposure; f, fever) or the CDC criteria [14] (IFA = 64; f, acute
febrile illness). Additional clinical laboratory findings typical for HGA: c, cytopenia;
le, elevated liver enzymes. Ecm, erythema chronicum migrans.
Research Notes 925
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 918–940
enzymes and leukopenia were detected in four of
these five patients. Notably, three of the five
serum samples from these patients contained
HGA IgM antibodies and were positive in the
western blot, and the patients had acquired the
tick-bites in the Berlin ⁄Brandenburg area. Three
of these cases also correspond with the definitions
of the Consensus Approach for Ehrlichiosis
(CAFE) Society [15]. Thus, the data suggest the
occurrence of autochthonous cases of HGA in
north-eastern Germany. However, based on the
European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) criteria [3], no
HGA case would be recognised, as even the
serum sample from the case that agreed closest to
this definition had a titre exactly four-fold, but not
> four-fold above the cut-off value.
Interestingly, only six HGA-positive samples
were detected in 1994–1997 among 273 serum
samples (2.2%, 95% CI 1.3–3.1%), compared with
13 HGA-positive samples detected among 149
samples (8.7%, 95% CI 6.9–10.5%) in 1998–2001
(p < 0.01). Asymmetric distributions were also
evident among the 22 HGA IgG-positive samples
(including controls), the IgM- or western blot-
positive samples (Fig. 1), and when only samples
with comparably high antibody titres (‡ 256) or
probable HGA cases were considered to be pos-
itive. Thus, although titres of HGA-specific anti-
bodies can persist for at least 2 years [16], an
asymmetric seroprevalencewas evident during the
8-year period of the study. Climate changes have a
direct impact on the epidemiology of vector-trans-
mitted infections [17], and there were no HGA
cases following the extremely cold winter of
1995 ⁄ 6, while in 1998, following a relatively warm
winter, six (14%) of 43 Borrelia-positive specimens
contained antibodies against A. phagocytophilum.
As the data are based on the relative prevalence
of HGA in Borrelia antibody-positive patients,
they may also reflect differences in the natural
cycles of HGA and borreliosis. Levin et al. [18]
demonstrated that the white-footed mouse (Pero-
myscus leucopus) is a more important amplifying
reservoir for B. burgdorferi than for A. phagocyto-
philum. More importantly, multiplication of
A. phagocytophilum in infected mice does not seem
to be efficient [19], and epidemiological studies
indicate that A. phagocytophilum infections of
rodents may be rather short-lived [20]. Thus, the
persistence of A. phagocytophilum in its vectors
seems to be more important for the maintenance
of the natural cycle than is persistence in infected
reservoir animals, and winter temperatures may
have a considerable impact on the numbers of
infected ticks. However, winter temperatures
could not readily explain the prevalence data in
other years, and other factors may also have an
impact on the transmission of A. phagocytophilum,
e.g., residents of Berlin could have travelled more
frequently to rural areas of Brandenburg follow-
ing the removal of the Berlin wall in 1989, and
might therefore have had increased exposure to
ticks.
Overall, the present study presents evidence for
the occurrence of autochthonous cases of HGA in
the Berlin ⁄Brandenburg area. The uneven annual
prevalence calls for further research on the eco-
logical relationships of this and other vector-
borne infections in order to design improved
control strategies.
R E F E R E N C E S
1. Blanco JR, Oteo JA. Human granulocytic ehrlichiosis in
Europe. Clin Microbiol Infect 2002; 8: 763–772.
2. Parola P, Davoust B, Raoult D. Tick- and flea-borne rick-
ettsial emerging zoonoses. Vet Res 2005; 36: 469–492.
3. Brouqui P, Bacellar F, Baranton G et al. Guidelines for the
diagnosis of tick-borne bacterial diseases in Europe. Clin
Microbiol Infect 2004; 10: 1108–1132.
4. Fingerle V, Goodman JL, Johnson RC, Kurtti TJ, Mund-
erloh UG, Wilske B. Human granulocytic ehrlichiosis in
southern Germany: increased seroprevalence in high-risk
groups. J Clin Microbiol 1997; 35: 3244–3247.
5. Hunfeld KP, Brade V. Prevalence of antibodies against the
human granulocytic ehrlichiosis agent in Lyme borreliosis
patients from Germany. Eur J Clin Microbiol Infect Dis 1999;
18: 221–224.
6. Woessner R, Gaertner BC, Grauer MT et al. Incidence and
prevalence of infection with human granulocytic ehrli-
Fig. 1. Annual distribution of serum samples positive for
human granulocytic anaplasmosis (including control spec-
imens) defined by positive IgG (black bars), IgM (grey
bars) and western blot (white bars).
926 Clinical Microbiology and Infection, Volume 12 Number 9, September 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 918–940
chiosis agent in Germany. A prospective study in young
healthy subjects. Infection 2001; 29: 271–273.
7. Matuschka FR, Heiler M, Eiffert H, Fischer P, Lotter H,
Spielman A. Diversionary role of hoofed game in trans-
mission of Lyme disease spirochetes. Am J Trop Med Hyg
1993; 48: 693–699.
8. Guillaume B, Heyman P, Lafontaine S, Vandenvelde C,
Delmee M, Bigaignon G. Seroprevalence of human gran-
ulocytic ehrlichiosis infection in Belgium. Eur J Clin
Microbiol Infect Dis 2002; 21: 397–400.
9. Groen J, Koraka P, Nur YA et al. Serologic evidence of
ehrlichiosis among humans and wild animals in The
Netherlands. Eur J Clin Microbiol Infect Dis 2002; 21: 46–49.
10. Lebech AM, Hansen K, Pancholi P, Sloan LM, Magera JM,
Persing DH. Immunoserologic evidence of human gran-
ulocytic ehrlichiosis in Danish patients with Lyme neuro-
borreliosis. Scand J Infect Dis 1998; 30: 173–176.
11. Oteo JA, Gil H, Barral M et al. Presence of granulocytic
ehrlichia in ticks and serological evidence of human infec-
tion in La Rioja, Spain. Epidemiol Infect 2001; 127: 353–358.
12. Unver A, Felek S, Paddock CD et al. Western blot analysis
of sera reactive to human monocytic ehrlichiosis and hu-
man granulocytic ehrlichiosis agents. J Clin Microbiol 2001;
39: 3982–3986.
13. Barbet AF, Meeus PF, Belanger M et al. Expression of
multiple outer membrane protein sequence variants from
a single genomic locus of Anaplasma phagocytophilum. Infect
Immun 2003; 71: 1706–1718.
14. Anonymous. Case definitions for infectious conditions
under public health surveillance. Centers for Disease
Control and Prevention. MMWR Recomm Rep 1997; 46: 1–
55.
15. Bakken JS, Dumler JS. Human granulocytic ehrlichiosis.
Clin Infect Dis 2000; 31: 554–560.
16. Lotric-Furlan S, Avsic-Zupanc T, Petrovec M et al. Clinical
and serological follow-up of patients with human gran-
ulocytic ehrlichiosis in Slovenia. Clin Diagn Laboratory
Immunol 2001; 8: 899–903.
17. Githeko AK, Lindsay SW, Confalonieri UE, Patz JA.
Climate change and vector-borne diseases: a regional
analysis. Bull WHO 2000; 78: 1136–1147.
18. Levin ML, des Vignes F, Fish D. Disparity in the natural
cycles of Borrelia burgdorferi and the agent of human
granulocytic ehrlichiosis. Emerg Infect Dis 1999; 5: 204–208.
19. Levin ML, Fish D. Immunity reduces reservoir host com-
petence of Peromyscus leucopus for Ehrlichia phagocytophila.
Infect Immun 2000; 68: 1514–1518.
20. Bown KJ, Begon M, Bennett M, Woldehiwet Z, Ogden NH.
Seasonal dynamics of Anaplasma phagocytophila in a rodent-
tick (Ixodes trianguliceps) system, United Kingdom. Emerg
Infect Dis 2003; 9: 63–70.
RESEARCH NOTE
Detection of Chlamydia trachomatis and
herpes simplex virus type 1 or 2 in cervical
samples in human papilloma virus
(HPV)-positive and HPV-negative women
R. R. Finan1, U. Musharrafieh2 and
W. Y. Almawi3
1Department of Obstetrics and Gynecology,
St Georges University Hospital, Beirut, 2Depart-
ment of Family Medicine, American University
of Beirut, Lebanon and 3Department of Medical
Biochemistry, Arabian Gulf University,
Manama, Bahrain
A B S T R A C T
This study investigated whether the prevalence of
human papilloma virus (HPV) in association with
Chlamydia trachomatis, herpes simplex virus
(HSV)-1 and ⁄ or HSV-2 was greater in high-grade
than in low-grade or control cervical biopsy
specimens. HPV-positive (n = 86) and HPV-neg-
ative (n = 213) women were screened for HPV,
HSV and C. trachomatis by PCR. The most com-
mon HPV genotypes were HPV-16, HPV-6 and
HPV-33; mixed HPV infection (n = 12) was also
seen. A higher prevalence of C. trachomatis, HSV-1
and HSV-2 was found in HPV-positive samples.
High-risk HPV genotypes and combined
HPV + C. trachomatis or HPV + HSV-1, but not
HSV-2, infections were associated with a greater
risk of developing cervical carcinoma.
Keywords Cervical carcinoma, Chlamydia trachoma-
tis, herpes simplex virus, human papilloma virus, risk-
factors
Original Submission: 7 December 2005; Revised
Submission: 15 January 2006; Accepted: 26 January
2006
Clin Microbiol Infect 2006; 12: 927–930
10.1111/j.1469-0691.2006.01479.x
Corresponding author and reprint requests: W. Y. Almawi,
Department of Medical Biochemistry, Arabian Gulf University,
PO Box 22979, Manama, Bahrain
E-mail: wyalmawi@yahoo.co.uk
Research Notes 927
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 918–940
